Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 281

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 281
---
 were as follows: (1) $108,397 for Mr. Sawhney, and (2) $187,500 for Dr. Eramo. Mr. Prensky received a $250,000 annual bonus
payment pursuant to the terms of the Prensky Separation Agreement, as described below under “—Potential Payments Upon Termination or Change in Control.”

In addition to the annual bonus, in May 2024, our board of directors (following the recommendation of our compensation committee) awarded
Dr. Eramo a discretionary bonus equal to $75,000.

Equity-Based Incentive Awards

Our equity-based incentive awards are designed to align our named executive officers’ interests with those of our stockholders and to
retain and incentivize our named executive officers over the long term. Our board of directors is responsible for approving equity grants. Vesting of equity awards is generally tied to continuous service with us and serves as an additional retention
measure. Our named executive officers generally are awarded an initial new-hire grant upon commencement of employment. Additional grants may occur periodically in order to specifically incentivize our named
executive officers with respect to achieving certain corporate goals or to reward our named executive officers for exceptional performance.

Prior to this offering, we have granted all equity awards pursuant to our 2017 Plan, 2018 Plan, and our 2023 Plan. Following this offering, we
will grant equity incentive awards under the terms of our 2025 Plan. The terms of our equity plans are described below under “—Equity Benefit Plans.” All options are granted with a per share exercise price equal to no less than the
fair market value of a share of our common stock on the date of the grant of such award. Generally, our option awards vest over a four-year period subject to the holder’s continuous service to us, as further described under
“—Outstanding Equity Awards as of December 31, 2024” below.

In June 2024, our board of directors granted
Mr. Prensky, Mr. Sawhney, and Dr. Eramo options to purchase 53,787, 34,065, and 6,275 shares of our common stock, respectively. In addition, in November 2024, our board of directors granted Ms. Turner an option to purchase
175,706 shares of our common stock. The terms of these awards are described under “—Outstanding Equity Awards as of December 31, 2024”